These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 23099497)

  • 21. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
    Lala C; Framme C; Wolf-Schnurrbusch UE; Wolf S
    Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
    Jackson TL; Chakravarthy U; Kaiser PK; Slakter JS; Jan E; Bandello F; O'Shaughnessy D; Gertner ME; Danielson L; Moshfeghi DM;
    Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between foveal microstructure and visual outcome in age-related macular degeneration.
    Shin HJ; Chung H; Kim HC
    Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
    Gomi F; Sawa M; Tsujikawa M; Nishida K
    Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J
    Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X; Hu Y; Sun X; Zhang J; Zhang M;
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
    Sabry D; Gad MA; Enam KM
    Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration.
    Üney GÖ; Ünlü N; Acar MA; Hazirolan D; Altiparmak UE; Yalniz-Akkaya Z; Örnek F
    Retina; 2014 Jan; 34(1):32-7. PubMed ID: 23751943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration.
    Parodi MB; Iacono P; La Spina C; Iuliano L; Lo Giudice G; Introini U; Bandello F
    Retina; 2014 Nov; 34(11):2167-70. PubMed ID: 24999724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
    Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
    Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration.
    Iacono P; Parodi MB; Introini U; La Spina C; Varano M; Bandello F
    Retina; 2014 Feb; 34(2):281-7. PubMed ID: 23851632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.